- recruiting
Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis
This study looks at how well the drug upadacitinib (RINVOQ) works for adults with ulcerative colitis in real-world settings. It follows people already prescribed the medication by their doctors in Germany, Austria, and Switzerland for up to two years.
Austria · Germany · Switzerland - recruitingPHASE3
Transfer of FRozen Encapsulated Multidonor Stool Filtrate for Active Ulcerative COlitis
This study is looking at new treatments for Ulcerative Colitis. We're testing if special capsules made from healthy donor stool can help people with active Ulcerative Colitis feel better. It involves comparing these capsules to a dummy pill to see if they are safe and effective.
Germany - ongoing, recruitingTherapeutic confirmatory (Phase III)
Evaluating the efficacy and safety of hyperbaric oxygen therapy as an adjuvant treatment compared to biologic therapy alone in moderate to severe ulcerative colitis in adults
This study is looking at a new way to treat severe ulcerative colitis. It tests if adding oxygen therapy to existing biologic medicines works better than biologics alone to reduce symptoms like diarrhoea and blood in your poo, and improve gut healing.
Poland - recruitingPHASE4
Bowel Preparation for Colonoscopy Among Individuals With Crohn's and Ulcerative Colitis Disease.
This study compares two bowel preparations, KleanLyte and Bi-PegLyte, for colonoscopies in people with Crohn's disease or ulcerative colitis. It aims to find out which is more effective at cleaning the bowel and easier to use before a colonoscopy.
Canada - recruitingPHASE2
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
This study is looking into new medicines, Eltrekibart and Mirikizumab, for adults with moderate to severe ulcerative colitis. Researchers want to see if these medicines are safe and if they can help people feel better.
United States · Argentina · Belgium - recruitingPHASE2
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
This study is testing new long-acting medicines for adults with moderate to severe ulcerative colitis. It aims to see how well they work and if they are safe, both on their own and in combinations, compared to a dummy treatment.
United States · Argentina · Australia - recruitingNA
Evaluation of Sleep Changes in Inflammatory Bowel Diseases (IBD) Patients.
This study looks at how sleep changes in people with Inflammatory Bowel Diseases (IBD) who are currently feeling well. We want to see if changes in sleep patterns might predict when their IBD symptoms could return or 'flare up'.
France - recruitingPHASE2
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
This study is testing a new medication, Tilpisertib Fosmecarbil, for adults with moderate to severe ulcerative colitis. It aims to see if the drug is safe and effective compared to a dummy pill (placebo) in improving symptoms.
United States · Australia · Austria - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A Clinical Trial to Assess the Safety of SOR102 in Healthy Participants and Patients with Ulcerative Colitis
Researchers are testing a new medicine called SOR102 for ulcerative colitis. This first study checks if it's safe in healthy people and those with the condition. It's an early step to see how SOR102 works in the body and if it could help patients in the future.
Bulgaria · Poland - recruitingPhase III
Study evaluating the efficacy of icotrokinra in ulcerative colitis
This study is testing a new medicine, icotrokinra, for ulcerative colitis (UC) in adults and teenagers. It aims to see if icotrokinra can help reduce UC symptoms and keep the disease under control by targeting inflammation.
United Kingdom · England · Scotland - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis
This study is looking at a medicine called Simponi for children and teenagers with a gut condition called ulcerative colitis. It wants to see if Simponi can help them feel better and heal their gut, and if it's safe to use.
Poland · France · Italy - ongoing, recruitingTherapeutic use (Phase IV)
VERDICT: In actiVE ulcerative colitis, a RanDomIzed Controlled Trial for determination of the optimal treatment target
This study, called VERDICT, looks at how best to treat ulcerative colitis. It compares different treatment goals using Entyvio, a common medication. The main aim is to see which treatment approach helps patients avoid colitis-related problems for the longest time.
Italy · Belgium · France - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy with PRA023 in Subjects with Moderately to Severely Active Ulcerative Colitis
This study is looking into a new medicine called tulisokibart for people aged 18 and over with moderate to severe ulcerative colitis. It aims to see if the medicine is safe and helps to reduce symptoms like stomach pain and bleeding, compared to a dummy treatment.
Czechia · Poland · France - ongoing, recruitingTherapeutic use (Phase IV)
A Prospective, Open-label Pilot Study to Evaluate Effector Mechanisms of Hyperbaric Oxygen Therapy in Patients with Moderate-to-Severe Ulcerative Colitis: The PARADOX study
This study, called PARADOX, investigates hyperbaric oxygen therapy (HBOT) for moderate-to-severe ulcerative colitis. Researchers want to understand how HBOT works at a very detailed level, looking at blood, gut lining, and gut bacteria to see if it helps reduce inflammation and symptoms.
Netherlands - recruitingPHASE3
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
This study looks at the long-term safety of a medicine called vedolizumab for children and young people with Crohn's disease or ulcerative colitis. It's for those who have already taken part in a previous study with vedolizumab.
United States · Australia · Belgium - authorisedTherapeutic exploratory (Phase II)
Debut of Ulcerative Colitis: selective Top-down strategy - the DUCT trial
This study looks at a new way to treat ulcerative colitis, a bowel condition. Researchers are testing if giving a specific drug early could help more people achieve 'deep remission' and avoid surgery or other strong medications in the first year after diagnosis.
Norway - authorisedHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine delayed release capsules 400 mg manufactured by Sun Pharmaceutical Industries Limited, India with Mesalamine Delayed-Release Capsules 400 mg, manufactured for Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054, in healthy, adult, human subjects under fed condition.
This study compares two different brands of mesalamine capsules, a medicine for ulcerative colitis, in healthy adults. It checks if they work the same way in the body after a single dose, under fed conditions.
Romania - ongoing, recruitingHuman Pharmacology (Phase I)- Other
Study to evaluate food effect on the pharmacokinetics of mesalazine oral formulation in healthy volunteers.
This study is looking at how a common medicine for ulcerative colitis, called mesalazine, is absorbed by the body when taken with food. It involves healthy volunteers and aims to help us understand the best way to take this medication.
Spain - recruiting
Nutrition and Clinical Outcomes in IBD
This study looks at how nutrition and body health affect people with Crohn's disease and ulcerative colitis. We want to find better ways to check for poor nutrition and understand how it impacts treatment, surgery, and overall well-being in IBD patients.
United Kingdom - active not recruitingPHASE3
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
This study compares two approved medicines, risankizumab and vedolizumab, for adults with moderate to severe ulcerative colitis who haven't tried similar treatments before. It looks at how safe and effective they are. Around 530 people will take part worldwide.
United States · Austria · Bulgaria - recruitingPHASE3
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
This study looks at a medicine called Mirikizumab for children and teenagers aged 2 to 19 with Ulcerative Colitis or Crohn's Disease. It checks how well the medicine works over a long time to help manage these conditions.
United States · Austria · Belgium - recruiting
PIBD-SETQuality: the Inception Cohort and Safety Registry
This study looks at how well current treatments work and their safety for children and teenagers with Inflammatory Bowel Disease (IBD). It wants to understand how individual factors might affect treatment outcomes and serious complications.
Netherlands · United Kingdom - authorisedHuman Pharmacology (Phase I)- Bioequivalence Study
A double blinded, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine Delayed Release Tablets USP 1.2 g manufactured by Sun Pharmaceutical Industries Limited, India with Mezavant (mesalamine) Delayed and Extended-Release Tablets 1.2 g product of Takeda Canada Inc., in healthy, adult, human subjects under fasting condition.
This study compares a new mesalamine tablet from India with an existing mesalamine tablet from Canada. It checks if the new tablet works in the same way in healthy adults. Mesalamine is a medicine used to treat ulcerative colitis.
Romania - recruitingPHASE3
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
This study is looking at a medicine called risankizumab for children and young people with ulcerative colitis (UC). It aims to see how well and safely it works, and how it moves through the body, for those aged 2 to 17 with moderate to severe UC.
United States · Belgium · Brazil - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
This study is testing a new medicine, Ozanimod, for people in the UK with moderate to severe ulcerative colitis. It's looking at how well the medicine helps control symptoms and improve the gut, as well as checking for any side effects. It's a key stage of testing before being widely available.
Belgium · Romania · Poland - ongoing, recruitingHuman Pharmacology (Phase I)- Other
Testing Insulin Enemas for Ulcerative Colitis: A First-Stage Clinical Trial
This study is looking at a new way to treat ulcerative colitis using insulin delivered as an enema. It's the very first time this treatment is being tested in people. The aim is to see if it's safe and how the body reacts to it.
Poland - authorisedPhase III and phase IV (Integrated)
IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITIS
This study looks at how certain medicines for ulcerative colitis might affect heart and blood vessel health. We want to see if these treatments change the thickness of neck artery walls or how stiff the main heart artery is in people with ulcerative colitis.
France - recruitingPHASE3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
This study looks at combining two medicines, mirikizumab and tirzepatide, for adults with ulcerative colitis (UC) who are also overweight or obese. The goal is to see if this combination helps UC symptoms improve and also leads to significant weight loss.
United States · Austria · Belgium - ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, multicenter phase 3 study in patients with moderately to severely active ulcerative colitis (UC) to compare the efficacy, safety and immunogenicity of PB016 and Entyvio® for the induction and maintenance of clinical response and remission. (UCESIVE)
This study compares a new medicine (PB016) with an existing one (Entyvio®) for adults with moderate to severe ulcerative colitis. It looks at how well they work to reduce symptoms and keep people well, as well as their safety.
Czechia · Poland · Romania - recruitingNA
Colectomy Reconstruction for Ulcerative Colitis, Ileorectal Anastomosis vs Ileal Pouch-Anal Anastomosis in Ulcerative Colitis.
This study compares two common surgeries to reconnect your gut after removing most of your large bowel for Ulcerative Colitis. It aims to see which one, an ileal pouch or an ileorectal anastomosis, offers the best quality of life, satisfaction, and fewer complications for patients in the UK.
Sweden · United Kingdom - ongoing, recruitingTherapeutic exploratory (Phase II)
A single arm, open-label study to evaluate the efficacy and safety of ABBV-668 in subjects with moderate to severe ulcerative colitis.
This study is testing a new medicine called ABBV-668 for people with moderate to severe ulcerative colitis. Doctors want to see if it helps improve the lining of the bowel after 8 weeks and if it's safe to use. It's a key step in understanding if this medicine could help patients.
Belgium · France · Poland - authorisedTherapeutic exploratory (Phase II)
T-FORE - Pilot study of a new technique of Oral Fecal Transplantation using frozen stool capsules for the maintenance treatment of pediatric Ulcerative Colitis (UC)
This study looks at a new way to treat Ulcerative Colitis in children using healthy gut bacteria from donor stool. They are testing both capsules and enemas to see which method works best to improve the gut’s natural balance over time.
France - active not recruiting
Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)
This study looks at how a medicine called filgotinib works for people with ulcerative colitis in everyday life. Researchers want to see if it helps with symptoms, improves quality of life, and if it's safe for people with moderate to severe disease.
Austria · Belgium · France - authorisedHuman Pharmacology (Phase I)- Bioequivalence Study
A double blinded, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine Delayed Release Tablets USP 1.2 g manufactured by Sun Pharmaceutical Industries Limited, India with Mezavant (mesalamine) Delayed and Extended-Release Tablets 1.2 g product of Takeda Canada Inc., in healthy, adult, human subjects under fed condition.
This study compares a new version of Mesalamine, a medicine for ulcerative colitis, with an existing one. We want to see if the new version works in the body in the same way as the old one, in healthy adults who have eaten.
Romania - active not recruitingPHASE3
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
This study is an extension for people in the UK with moderately to severely active ulcerative colitis who have already taken part in a specific etrasimod trial. It aims to gather more information on the long-term safety and effectiveness of etrasimod for this condition.
United States · Argentina · Australia - ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Phase 2 Induction Study with Long-Term Extension to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants with Moderate to Severe Ulcerative Colitis
This study is testing a new medicine called NX-13 for people in the UK with moderate to severe ulcerative colitis. Researchers want to see if it helps reduce symptoms and is safe compared to a dummy pill.
Belgium · Poland · Italy - active not recruitingPHASE3
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
This study is testing a new medicine, tulisokibart, for people with moderate to severe ulcerative colitis. It aims to see if the medicine can help people feel better and stay in remission, compared to a dummy medicine, both in the short and long term.
United States · Argentina · Australia - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multi-Center, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Pediatric Subjects with Ulcerative Colitis Who Completed the Study M11-290
This study looks at the long-term safety of a treatment called Humira for children and teens with ulcerative colitis. It's for those who have already been on Humira in a previous study. We want to see how well they continue to do.
Slovakia · Poland - recruiting
NAZA - Nottingham/Astra ZenecA Prospective IBD Cohort Study
This study compares body markers linked to inflammation in people with Crohn's disease or ulcerative colitis (IBD) and healthy individuals. It aims to understand IBD better and find ways to predict treatment responses, ultimately leading to improved care.
United Kingdom - active not recruitingPHASE2
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called emvistegrast for people with moderate to severe ulcerative colitis. It aims to see if emvistegrast can help improve their symptoms compared to a dummy medicine.
United States · Australia · Austria - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Ulcerative Colitis
This study is testing a new medicine called Rosnilimab for people with moderate to severe Ulcerative Colitis. Researchers want to see if it helps reduce symptoms and improve gut health compared to a dummy treatment, and if it's safe to use.
France · Germany · Austria - active not recruiting
An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice
This study looks at how a medicine called upadacitinib works for adults with moderate to severe Ulcerative Colitis in everyday life. Researchers will check its safety and how well it helps manage the condition, following about 1000 people over three years.
Argentina · Australia · Canada - recruitingPHASE2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
This study is looking into a new treatment, RO7837195, for people with moderate to severe ulcerative colitis whose usual treatments haven't worked well. It aims to see if the new drug is safe and effective in helping manage the condition.
United States · Australia · Brazil - ongoing, recruitingTherapeutic exploratory (Phase II)
Orismilast for the treatment of moderate to severe ulcerative colitis
This study is looking into a new medicine called Orismilast for people in the UK with moderate to severe ulcerative colitis. It's a Phase II trial, meaning it's still in the earlier stages of testing. Researchers want to see if the medicine can help people feel better by reducing symptoms.
Denmark - authorisedTherapeutic exploratory (Phase II)
Multi-center, single-arm, phase II clinical trial evaluating efficacy and in-vivo homing of adoptively transferred autologous ex-vivo expanded regulatory T cells in adults with ulcerative colitis
This study is testing a new cell therapy for adults with ulcerative colitis. It involves taking your own immune cells, growing more of them in a lab, and then giving them back to you. Researchers want to see if this helps reduce symptoms within 12 weeks.
Germany - active not recruitingPHASE3
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called mirikizumab for adults with ulcerative colitis. It aims to see how well it helps reduce urgent bowel movements in people with moderate to severe disease, especially if other treatments haven't worked.
United States · Belgium · Czechia - recruitingPHASE2
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
This study is testing a new drug, SAR442970, for adults with moderate to severe Ulcerative Colitis. It compares different doses of the drug to a dummy pill to see if it helps reduce symptoms and is safe.
United States · Australia · China - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1b, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB310 in Patients with Active, Mild to Moderate Ulcerative Colitis (COMPOSER-1)
This study is looking into a new treatment called MB310 for people with ulcerative colitis. It's an early-stage trial checking if the treatment is safe, how well it settles in the body, and if it shows any early signs of helping patients with mild to moderate symptoms.
Austria · Poland · Bulgaria - active not recruitingPHASE2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
This study looks at a new medicine called TAK-279 for adults with moderate to severe ulcerative colitis. It aims to see if it reduces bowel inflammation and symptoms compared to a dummy medicine, and to check for any side effects.
United States · Australia · Belgium - active not recruitingPHASE3
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
This study is looking at a medicine called tofacitinib for children aged 2-17 with a bowel condition called ulcerative colitis. It aims to see how well it works, how safe it is, and how the body uses it, especially if other treatments haven't worked.
United States · Australia · Belgium